Skip to main content
Premium Trial:

Request an Annual Quote

Hyseq Losses Dwindle, Revenues Climb for Q2

NEW YORK, July 25-Hyseq today reported a small decrease in net losses and a modest increase in revenues for the second quarter of 2002.


For the three months ended June 30, 2002, Hyseq reported a net loss of $8.1 million, or $0.37 per share. Losses for the second quarter 2001 were $8.4 million, or $0.55 per share.


Hyseq said that its revenues for the quarter had climbed to $11.9 million from $11.6 million for the equivalent quarter in 2001.


During the second quarter of 2002, the company also pocketed about $15 million from a private stock placement.


R&D expenditures dwindled slightly, from $11 million in the second quarter of 2001 to $10.7 million in Q2 2002.


Hyseq said it had $11.8 million in cash on hand as of June 30, 2002.


For more information, see the company quarterly report.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.